Skip to main content
Back to Shenzhen Capital Group

Shenzhen Capital Group's Biotechnology Portfolio

Browse 13 Biotechnology companies funded by Shenzhen Capital Group. See funding amounts, founder contacts, and investment details.

Biotechnology Companies
13
Total Funding in Biotechnology
$240.7M

Biotechnology Portfolio Companies (13)

Export
BiotechnologyHealth CareTherapeutics

Regend Therapeutics focuses on the human organ regenerative medicine business

Suzhou, China
February 2026
$50.6M
Series C

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalMedical Device

Transcend Vivoscope is a biotechnology company that specializes in providing advanced microscopy imaging products and solutions.

Haidian, China
February 2026
$14.5M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyFood and BeverageManufacturing

Weiyuan Synthetic Biotechnology specializes in the manufacturing of food, feed and materials based on synthetic biology technology.

Beijing, China
January 2026
$42.9M
Series Unknown

Founder Contacts

19,000+ verified contacts

BiotechnologyHealth CareProduct Research

MAXVAX aims to provide novel vaccine development and commercialization.

Shuangliu, China
December 2025
Series D

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyPharmaceutical

Weike Bio is a gene therapy drug development company.

Minhang, China
November 2025
$14.1M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyMedicalProduct Research

Cytocares offers innovative drug design for antibody novel medication creation and development in the realm of tumor immunity.

Shanghai, China
October 2025
Series A

Founder Contacts

19,000+ verified contacts

BioinformaticsBiotechnologyGeneticsMedical

Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products.

Shenzhen, China
October 2025
$7.0M
Series B

Founder Contacts

19,000+ verified contacts

BiotechnologyMedical

Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.

Nanjing, China
September 2025
$28.1M
Series A

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyWellness

Yantai Lannacheng Biotechnology is a biotech business that focuses on the building class I diagnosis medication.

Yantai, China
July 2025
$41.8M
Series C

Founder Contacts

19,000+ verified contacts

Biotechnology

Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis.

Suzhou, China
March 2025
$13.8M
Series B

Founder Contacts

19,000+ verified contacts

BiopharmaBiotechnologyHealth CareMedical

Wingtech Pharmaceuticals is an innovative pharmaceutical company that develop drugs for the treatment of chronic metabolic diseases.

Suzhou, China
October 2024
Series B

Founder Contacts

19,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyLife ScienceMedical

MoleculeMind is an AI-integrated biotech firm that fuses artificial intelligence with biotechnology to form a new development platform.

Haidian, China
September 2024
$14.0M
Series A

Founder Contacts

19,000+ verified contacts

BiotechnologyHospitalMedical

Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies.

Shanghai, China
April 2024
$13.8M
Series A

Founder Contacts

19,000+ verified contacts

Explore Shenzhen Capital Group's Full Portfolio

View all companies funded by Shenzhen Capital Group across every industry and funding stage.

View Full Shenzhen Capital Group Portfolio